Friday 25 January 2019

Teriflunomide shows long term benefits in patients with Multiple Sclerosis

Mark Freedman, MD, FAAN of Ottawa Hospital has done some lengthy investigations on using Teriflunomide for the treatment of relapsing forms of Multiple Sclerosis. It has shown to reduce relapses slowing disability and reducing MRI activity.

It has been found that patients on 13 years trial period did good and shown very less relapse with no significant change in disability.

Teriflunomide is taken as a single dose of 14mg or as two times in a day as 7mg. 

The most desired dosage is of taking once a day 14mg with or without food. Preferably in the morning.

No comments:

Post a Comment